U.S. Auto Stock News

Vail Resorts reported that, after the close of its nomination window, activist investor Oasis Management and other shareholders submitted slates to nominate Robert A. Chapek, M. Ashton Hudson, Bryce Roberts, and Picabo Street for board seats. The company is also conducting a separate search for an additional independent director into early 2027. The contest over board seats highlights how Vail Resorts’ governance is being challenged at the same time the business faces less predictable...

Gilead Sciences (GILD) just saw its herpes simplex virus collaboration with Assembly Biosciences deepen, as Assembly opted into a 40% U.S. cost and profit share on the HSV helicase primase program. The Gilead Sciences share price has climbed 18.19% year to date and 14.44% over the past 90 days, while the 1-year total shareholder return of 28.73% and 3-year total shareholder return above 2x suggest momentum has been building as investors weigh recent product approvals, legal wins and expanded...

XPeng (NYSE:XPEV) reported August 2026 vehicle deliveries of 39,107 units, a 4% year over year increase, giving investors fresh data on how the physical AI focused automaker is converting interest into actual sales. The fresh delivery update comes amid a weak price backdrop for XPeng, with the share price down 10.3% over the past 30 days and 48.4% year to date, while the 1-year total shareholder return has declined 49.5%. This signals that recent momentum has been fading despite improving...

MannKind stock has fallen about 33% year to date, yet several valuation checks, including an intrinsic value estimate using a Discounted Cash Flow (DCF) approach, point to a price that sits below what those models suggest. That gap, combined with mixed signals from broader valuation screens, puts the current share level under closer scrutiny for investors trying to assess what is already priced in. The share price has declined roughly 33% year to date, which means sentiment has cooled...

Amgen (NasdaqGS:AMGN) reported Phase 3 DeLLphi-305 results for IMDELLTRA in first-line maintenance extensive stage small cell lung cancer. The study is described as the first Phase 3 trial to show an overall survival benefit for a BiTE therapy in this setting. Management positioned the positive DeLLphi-305 outcome as a key milestone for Amgen's oncology franchise and treatment options in small cell lung cancer. The DeLLphi-305 survival data for IMDELLTRA adds fresh context to the broader...

The market barely flinched on Yuanbao, with the stock up just 2% today, yet the earnings story was far louder than the price move suggests. You saw a routine green day. The company printed a sharp Q2 headline, with revenue of RMB 1.39b and net income of RMB 413.2m. That left a net margin of 29.7%, a powerful figure for an online insurance platform. In the short term, the share price reaction looks cautious. The gap between that restraint and the strength of the profitability trend is where...

A new global carbon fiber report has put Hexcel (HXL) in focus, naming the producer among leading suppliers to aerospace, wind energy, electric vehicles, hydrogen storage, and recycled carbon markets. Hexcel shares closed at US$92.74 after a 3.25% 1-day share price return, while the stock is still down 9.35% on a 30-day share price basis and 5.09% over 90 days. The 1-year total shareholder return of 50.93% and 5-year total shareholder return of 66.02% indicate momentum that has built over a...

Bilibili (BILI) has completed a zero coupon, callable and convertible Eurobond offering of US$700 million in senior unsecured notes due September 15, 2031, adding Goldman Sachs and Morgan Stanley Asia as co-lead underwriters. Bilibili’s share price has been weak this year, with the stock down 41.07% year to date and a 30 day share price return of 11.75% in decline, even though the 3 year total shareholder return of 12.61% hints at patchy but not uniform long term momentum. Scan beyond...

Strategy stock has delivered a very strong 3 year gain while the broader valuation checks still lean expensive, leaving recent buyers weighing momentum against what the numbers are saying about value today. Over the past 3 years, Strategy has returned about 2.8x, which puts recent share price weakness into the context of a very large multi year run. Management’s renewed commitment to Bitcoin accumulation and the creation of DeFi yield products tied to its preferred stock can support the...

T-Mobile US (TMUS) just tied its latest iPhone 18 lineup launch to aggressive trade in credits, extended 36 month financing and new iPhone Handoff features. This gives investors fresh data on the company’s device driven customer acquisition approach. T-Mobile US has had a choppy run into this iPhone 18 campaign, with the share price up 2.92% on the day to US$182.33 yet still recording a year to date share price return that is down 8.64% and a 1 year total shareholder return that is down...

TraceLink announced that its DSCSA compliance platform has been integrated into Omnicell’s central pharmacy inventory systems, allowing hospital pharmacies to handle product verification, traceability, and audit-ready reporting directly within existing medication receiving workflows. This tie-up plugs Omnicell customers into TraceLink’s large authenticated supply chain network, which may ease compliance workloads for hospital teams already facing operational and cost pressure. Next, the...

Campbell's stock has retreated sharply over the past few years, yet some of the current valuation checks still view the shares as not outright expensive or cheap. Recent cost cuts, a reduced dividend and weaker profitability now sit against a mixed read on value rather than a clear bargain. The share price has fallen 44.2% over the past three years, which signals that investors have been marking down expectations for the business. A planned US$500m cost reduction program can support margins...

Kaspi.kz (KSPI) has approved a KZT 1,000 dividend per common share for the second quarter of 2026 at its Extraordinary General Meeting, with payments scheduled to begin on 9 September 2026. Kaspi.kz shares closed at $99.96 on 10 September, with a 1 day share price return of 2.89% after the dividend news, while the 90 day share price return of 24.08% and 1 year total shareholder return of 26.30% indicate that momentum has been building rather than fading. Scan other dividend heavyweights with...

Gorman-Rupp reported record second quarter net sales and earnings per share, supported by solid demand from construction, agriculture, and data center projects, alongside strong operating cash flow that allowed further debt reduction and continued reinvestment in the business. Healthy incoming orders and backlog painted a firm operational picture, yet investor reaction stayed cautious, suggesting concerns about how these record results align with earlier expectations and future demand...

Axsome Therapeutics recently reported that the first patient has been dosed in SUMMIT, a Phase 3 trial evaluating AXS-05 for smoking cessation against bupropion and placebo over 12 weeks. The primary endpoint is abstinence at week 12. The SUMMIT study evaluates whether Axsome Therapeutics can extend AXS-05 beyond its current approvals. This would broaden the product’s potential use while leveraging a patent estate that runs at least to 2043. This article examines how Axsome Therapeutics'...

Realty Income presents an unusual valuation split right now, with its Discounted Cash Flow (DCF) intrinsic value estimate pointing to a large gap to the upside, while traditional market multiples suggest the stock is not cheap and the broader value score reads as weak. Over the past 3 years, Realty Income has returned about 29.9%, which suggests the long term income story has still been rewarded even through recent share price softness. The 5.3% dividend yield and long record of monthly...

Astera Labs has climbed 62.2% year to date, yet valuation checks point to a stock that appears expensive on most measures and only roughly aligned with its intrinsic value estimate rather than clearly cheap. The 62.2% year to date gain sets a high bar for future returns and leaves little room for disappointment in the story investors are paying for. Expectations for ongoing growth in high speed connectivity solutions can support the current share price, while any slowdown in cash flow...

BioMarin Pharmaceutical (NasdaqGS:BMRN) reported positive Phase 3 VOXZOGO results in children with hypochondroplasia, published in NEJM Evidence. The company filed a supplemental application with the FDA to expand VOXZOGO’s label as a targeted therapy for hypochondroplasia. VOXZOGO is positioned as a potential first approved treatment for hypochondroplasia, building on its existing indication in achondroplasia. The new VOXZOGO hypochondroplasia data and FDA filing come alongside broader...

The market finally blinked. Macy’s stock jumped 7.7% to US$22.08 after earnings, even though the past 90 days left holders down about 13%. Traders rushed back in because the headline was simple enough to cut through the noise. Comparable sales rose 2.7% and adjusted earnings per share landed at roughly US$0.64. That move is really a verdict on one thing. The retailer showed that its “Bold New Chapter” playbook can produce higher comps and a 41.5% gross margin in a tough department store...

OUTFRONT Media (OUT) is set to present at Citi’s 2026 Global TMT Conference in New York on September 8, 2026, with Chief Executive Officer Nick Brien scheduled to speak. Recent trading has been choppy for OUTFRONT Media, with the share price slipping 4.7% over the past month and 8.7% over the last quarter, even after a 20.7% year to date share price return and a 58.2% total shareholder return over the past year. This points to longer term momentum holding up while shorter term sentiment cools...

IDEX stock has delivered a 41.7% gain over the past year, yet the valuation picture is split, with an intrinsic value estimate pointing to upside while traditional market multiples lean the other way. For investors, that contrast raises questions about how much of IDEX's cash flow potential is already reflected in the current share price around US$224. The 41.7% 1 year return signals strong recent enthusiasm for IDEX, which can limit the margin of error if expectations prove too...

UiPath (NYSE:PATH) released a global report highlighting orchestration as a key factor in scaling agentic AI beyond pilots. The research draws on enterprise survey data that points to connecting data, systems, and employees as a main adoption challenge. Philippines based PLDT Inc. used UiPath orchestration to roll out agentic AI at scale, reporting large productivity gains and faster customer response. UiPath's new orchestration report and the PLDT deployment are only part of the broader...

Board refresh puts governance in focus for AT&T AT&T (T) just expanded its board from 10 to 11 directors, bringing in Fazal F. Merchant, a veteran finance executive with extensive transaction and technology experience. Merchant joins both the Audit and the Corporate Development and Finance Committees. This places him close to oversight of AT&T’s balance sheet, capital allocation and potential deal activity at a time when investors are watching those areas closely. AT&T shares have picked up...

PTC (PTC) has drawn investor attention after recent trading left the stock down about 12% over the past month, even as the past 3 months show a gain of roughly 15%. Viewed over a longer stretch, PTC’s recent slide fits into a tougher year, with the year to date share price return down 23.12% and the 1 year total shareholder return declining 36.24%, even though the 90 day share price return is up 15.04%. Scan how PTC compares to other software names under pressure this year by reviewing our...